生物疗法的使用在治疗白皮病的管理:一个系统的审查
Michele Zaman1, Rebeca Martinez2, Omkar Mayur2
1School of Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.
Archives of dermatological research
|August 19, 2024
概括
生物疗法,包括infliximab和adalimumab,显示出在治疗皮肤炎 (PG) 中的卓越疗效. 这一系统性审查发现了高分辨率,表明生物制剂是这种具有挑战性的皮肤状况的有希望的选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮肤质 (PG) 治疗缺乏标准化的指导方针和有效的选择.
- 生物疗法为管理PG提供了潜在的新途径.
研究的目的:
- 系统地审查生物疗法在治疗白皮病治疗中的疗效.
- 总结目前关于PG生物治疗结果的证据.
主要方法:
- 在2022年9月22日之前对PubMed/MEDLINE,EMBASE和Cochrane数据库进行系统审查.
- 包括82项同行评审的研究,涉及108名患有松性皮肤病的患者.
- 分析常用的生物药物,如infliximab,adalimumab和etanercept.
主要成果:
- 恩弗利西玛布,阿达利穆马布和埃坦塞普特是最常用的生物药物.
- 88.9%的患者通过生物疗法实现了完全的PG解脱.
- 改善的平均时间为30天,解决的平均时间为161天.
结论:
- 生物疗法在治疗白皮病治疗中表现出很高的疗效.
- 这些药物对PG患者来说是一个有吸引力的治疗选择.
- 进一步的研究可能会完善用于PG的生物治疗方案.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Gastritis III: Clinical Manifestations and Management
192
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
192
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78


